Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Antibodies against oxidized low-density lipoprotein for the treatment of vulnerable plaques

Nilsson, Jan LU ; Glaser, S and Carlsson, R (2006) In Current Opinion in Investigational Drugs 7.
Abstract
Inflammation caused by the accumulation of oxidized low-density lipoprotein (oxLDL) in the arterial wall is a key factor in the development of atherosclerosis. Accumulating evidence suggests that adaptive immune responses to oxLDL are of major importance in regulating the inflammatory response, and that humoral immunity largely has a protective effect in this process. This concept is supported by animal studies demonstrating that treatment with antibodies against oxLDL inhibits atherosclerosis. Human antibodies with high affinity and specificity for epitopes on oxLDL have been developed and are now, after appropriate safety testing and non-clinical toxicology, ready to be tested in humans. Patients that may benefit front antibody treatment... (More)
Inflammation caused by the accumulation of oxidized low-density lipoprotein (oxLDL) in the arterial wall is a key factor in the development of atherosclerosis. Accumulating evidence suggests that adaptive immune responses to oxLDL are of major importance in regulating the inflammatory response, and that humoral immunity largely has a protective effect in this process. This concept is supported by animal studies demonstrating that treatment with antibodies against oxLDL inhibits atherosclerosis. Human antibodies with high affinity and specificity for epitopes on oxLDL have been developed and are now, after appropriate safety testing and non-clinical toxicology, ready to be tested in humans. Patients that may benefit front antibody treatment are most likely to be high-risk individuals in which conventional treatments, including lipid-lowering statins, do not provide sufficient protection. (Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Current Opinion in Investigational Drugs
volume
7
article number
815
publisher
BioMed Central (BMC)
external identifiers
  • scopus:33748672080
ISSN
2040-3429
language
English
LU publication?
yes
id
5fea7299-829d-4073-bdb3-a3cd68975aa7 (old id 1135999)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/17002259
date added to LUP
2016-04-01 11:45:17
date last changed
2020-01-12 08:32:35
@article{5fea7299-829d-4073-bdb3-a3cd68975aa7,
  abstract     = {Inflammation caused by the accumulation of oxidized low-density lipoprotein (oxLDL) in the arterial wall is a key factor in the development of atherosclerosis. Accumulating evidence suggests that adaptive immune responses to oxLDL are of major importance in regulating the inflammatory response, and that humoral immunity largely has a protective effect in this process. This concept is supported by animal studies demonstrating that treatment with antibodies against oxLDL inhibits atherosclerosis. Human antibodies with high affinity and specificity for epitopes on oxLDL have been developed and are now, after appropriate safety testing and non-clinical toxicology, ready to be tested in humans. Patients that may benefit front antibody treatment are most likely to be high-risk individuals in which conventional treatments, including lipid-lowering statins, do not provide sufficient protection.},
  author       = {Nilsson, Jan and Glaser, S and Carlsson, R},
  issn         = {2040-3429},
  language     = {eng},
  publisher    = {BioMed Central (BMC)},
  series       = {Current Opinion in Investigational Drugs},
  title        = {Antibodies against oxidized low-density lipoprotein for the treatment of vulnerable plaques},
  url          = {http://www.ncbi.nlm.nih.gov/pubmed/17002259},
  volume       = {7},
  year         = {2006},
}